TuHURA Biosciences Inc Dossier - Source-backed chat

TuHURA Biosciences Inc

HURANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.34

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.10Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $133.8M

Enterprise Value $136.4M

Shares Outstanding 64.9M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

TuHURA Biosciences is a late-stage, Phase 3 registration-stage immuno-oncology company uniquely positioned to address the massive clinical challenge of immunotherapy resistance. Its lead asset, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors and is currently being evaluated in a pivotal Phase 3 trial as an adjunctive therapy to Keytruda for advanced or metastatic Merkel Cell Carcinoma (MCC). The company's financial runway has been significantly de-risked through a newly established $50 million non-equity revolving credit facility from an affiliate of its largest stockholder, extending its cash runway into 2028 and fully funding operations through the anticipated Phase 3 top-line readout in 2H 2027. Additionally, the acquisition of Kineta has expanded its pipeline with TBS-2025, a promising VISTA-inhibiting antibody targeting AML and MDS, which is poised to enter Phase 1b/2 clinical trials in 2H 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.20

Mean target$8.04

High · most bullish analyst$10.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5020%

The Phase 3 trial of IFx-2.0 experiences significant enrollment delays beyond 2H 2027 or fails to show a statistically significant improvement in ORR compared to Keytruda alone. TBS-2025 encounters safety hurdles or regulatory holds during its Phase 1b/2 trial. High interest expenses from drawing down on the 12% credit facility strain the company's balance sheet, forcing a highly dilutive equity restructuring or asset sales.

Base CaseCentral scenario

$8.5750%

IFx-2.0 successfully completes enrollment in 2H 2027 and delivers positive top-line Phase 3 results, validating its mechanism of action and supporting a path toward regulatory submission. TBS-2025 successfully initiates its Phase 1b/2 trial in 2H 2026 with manageable safety and initial signs of efficacy. The company utilizes its $50 million credit facility to fund operations through 2028, avoiding highly dilutive equity raises at depressed valuations.

Bull CaseUpside scenario

$10.5030%

The Phase 3 trial of IFx-2.0 in combination with Keytruda meets its primary endpoint of Objective Response Rate (ORR) with high statistical significance, leading to accelerated FDA approval in 2028. TBS-2025 demonstrates strong early efficacy in mutNPM1 r/r AML, triggering a lucrative co-development partnership with a major pharmaceutical company. The non-equity credit facility prevents near-term dilution, allowing existing shareholders to capture the full upside of these clinical milestones.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pivotal Phase 3 asset (IFx-2.0) targeting a high-value, underserved indication (Merkel Cell Carcinoma) with a clear regulatory path under an FDA Special Protocol Assessment (SPA).
Secured $50 million non-equity credit facility extending cash runway into 2028, eliminating immediate dilution risk and funding operations through key Phase 3 data readouts.
Diversified pipeline with TBS-2025 (VISTA inhibitor) entering Phase 1b/2 in 2H 2026, and a novel bi-specific ADC platform targeting Myeloid Derived Suppressor Cells (MDSCs)

Key Investment Risks

Clinical trial risk: The company is pre-revenue and entirely dependent on the clinical and regulatory success of its pipeline candidates.
Financial burden: The $50 million credit facility carries a high 12% annual interest rate and is secured by substantially all assets, adding significant debt service pressure.
Royalty obligations: The credit facility agreement grants the lender a low-to-mid single-digit royalty on future commercial sales of IFx-2.0, reducing long-term profitability.

Thesis Invalidation Triggers

Failure of the Phase 3 IFx-2.0 trial to meet its primary endpoint of Objective Response Rate.
FDA refusal to approve the IND or clinical hold on the TBS-2025 Phase 1b/2 trial.
Inability to draw down on the credit facility due to covenant defaults or disputes with the lender.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.